Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
BACKGROUND
There are conflicting data on the use of cilostazol as triple antiplatelet therapy (TAPT) for improving clinical outcomes after drug-eluting stent implantation. We aimed to evaluate whether 3-month use of cilostazol in addition to dual antiplatelet therapy (DAPT) improved clinical outcomes in patients with long or multivessel coronary artery disease (CAD) after biolimus-eluting stent (BES) implantation.


METHODS
Patients (n = 630) who had been successfully treated with BES implantation for lesions with ≥28 mm in stent length or ≥2 stents for different coronary arteries were enrolled in this prospective randomized multicenter trial. All patients were randomly assigned to receive either DAPT (aspirin and clopidogrel for 12 months, n = 314) or TAPT (DAPT plus 3-month cilostazol use, n = 316). The primary end point was a device-oriented composite consisting of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel), and ischemia-driven target lesion revascularization at 1-year follow-up.


RESULTS
A total of 314 patients in DAPT and 308 patients in TAPT were analyzed. Multivessel CAD was present in 65.7% of patients. Stents ≥28 mm in length were implanted in 58.1% of lesions. There were no significant differences in baseline and angiographic characteristics between the 2 groups. The primary end point was similar between the 2 groups (2.3% in DAPT vs 1.9% in TAPT, log-rank P = .799).


CONCLUSIONS
In patients treated with BES implantation for long or multivessel CAD, 3 months of cilostazol use in addition to DAPT did not improve clinical outcome at 1-year follow-up.
Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea. Electronic address: jyoon@yonsei.ac.kr.
Young Jin
YJ
Youn
Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea.
Jun-Won
JW
Lee
Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea.
Sung Gyun
SG
Ahn
Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea.
Seung-Hwan
SH
Lee
Division of Cardiology, Inje University Ilsan Paik Hospital, Goyang, South Korea.
Hyunmin
H
Choi
Division of Cardiology, Sejong General Hospital, Bucheon, South Korea.
Cheol Woong
CW
Yu
Division of Cardiology, Chonnam National University Hospital, Gwangju, South Korea.
Young Joon
YJ
Hong
Division of Cardiology, Yonsei University Gangnam Severance Hospital, Seoul, South Korea.
Hyuck Moon
HM
Kwon
Division of Cardiology, Yonsei University Severance Cardiovascular Hospital, Seoul, South Korea.
Myeong-Ki
MK
Hong
Division of Cardiology, Yonsei University Severance Cardiovascular Hospital, Seoul, South Korea.
Yangsoo
Y
Jang
Division of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea.
Junghan
J
Yoon
D000368:Aged; D000077407:Cilostazol; D000077144:Clopidogrel; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011446:Prospective Studies; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D013777:Tetrazoles / Q000008:administration & dosage*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; C518022:umirolimus; D020123:Sirolimus